Citations (67)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (16)
Yajnavalka Banerjee, Anca Pantea Stoian, José Silva-Nunes, Alper Sonmez, Ali A. Rizvi, Andrej Janez & Manfredi Rizzo. (2021) The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism. Expert Opinion on Drug Safety 20:11, pages 1309-1315.
Read now
Read now
Haoran Wang, Yue Li, Xiaoliang Zhang, Zhonglin Xu, Jianzhong Zhou & Wei Shang. (2020) DPP-4 Inhibitor Linagliptin Ameliorates Oxidized LDL-Induced THP-1 Macrophage Foam Cell Formation and Inflammation. Drug Design, Development and Therapy 14, pages 3929-3940.
Read now
Read now
Angelo Maria Patti, Rosaria Vincenza Giglio, Nikolaos Papanas, Manfredi Rizzo & Ali A. Rizvi. (2019) Future perspectives of the pharmacological management of diabetic dyslipidemia. Expert Review of Clinical Pharmacology 12:2, pages 129-143.
Read now
Read now
Xueying Tan & Jingbo Hu. (2016) Evogliptin: a new dipeptidyl peptidase inhibitor for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy 17:9, pages 1285-1293.
Read now
Read now
Ali A Rizvi, Angelo Maria Patti, Rosaria Vincenza Giglio, Dragana Nikolic, Antonella Amato, Noor Al-Busaidi, Khalid Al-Rasadi, Maurizio Soresi, Maciej Banach, Giuseppe Montalto & Manfredi Rizzo. (2015) Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study. Expert Opinion on Biological Therapy 15:10, pages 1391-1397.
Read now
Read now
Dragana Nikolic, Peter P Toth, Alessandra Ferlita, Vittoria Di Bartolo, Giuseppe Montalto, Maciej Banach & Manfredi Rizzo. (2014) Novel anti-obesity drugs and plasma lipids. Clinical Lipidology 9:2, pages 179-187.
Read now
Read now
John Gerich. (2013) Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies. International Journal of General Medicine 6, pages 877-895.
Read now
Read now
Manfredi Rizzo, Angelo Avogaro, Giuseppe Montalto & Ali A Rizvi. (2013) Non-glycemic effects of pioglitazone and incretin-based therapies. Expert Opinion on Therapeutic Targets 17:7, pages 739-742.
Read now
Read now
Sana Khan, Saba Khan, Mohammed Imran, Krishna Kolappa Pillai, Mohd Akhtar & Abul Kalam Najmi. (2013) Effects of pioglitazone and vildagliptin on coagulation cascade in diabetes mellitus – targeting thrombogenesis. Expert Opinion on Therapeutic Targets 17:6, pages 627-639.
Read now
Read now
Pablo Perez- Martinez, Manfredi Rizzo, Giuseppe Montalto & Jose Lopez- JMiranda. (2013) Postprandial metabolism: from research to clinical practice. Clinical Lipidology 8:4, pages 395-398.
Read now
Read now
André J. Scheen. (2013) Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors: From Risk Factors to Clinical Outcomes. Postgraduate Medicine 125:3, pages 7-20.
Read now
Read now
Manfredi Rizzo, Dragana Nikolic, Maciej Banach, Rosaria Vincenza Giglio, Angelo Maria Patti, Vittoria Di Bartolo, Annamaria Tamburello, Antonella Zabbara, Giuseppina Pecoraro, Giuseppe Montalto & Ali A Rizvi. (2013) The effects of liraglutide on glucose, inflammatorymarkersandlipoprotein metabolism: current knowledge and future perspective. Clinical Lipidology 8:2, pages 173-181.
Read now
Read now
Edoardo Mannucci & Ilaria Dicembrini. (2012) Incretin-based therapies and cardiovascular risk. Current Medical Research and Opinion 28:5, pages 715-721.
Read now
Read now
André J Scheen. (2012) A review of gliptins in 2011. Expert Opinion on Pharmacotherapy 13:1, pages 81-99.
Read now
Read now
Manfredi Rizzo, Gerald H Tomkin, Maria Patti Angelo, Ilenia Pepe, Rosa Valerio Maria, Salvatore Di Rosa, Battista Rini Giovam & Gaetana D Fede. (2011) Effects of hypolipidemic and hypoglycemic agents on atherogenic small, dense LDL in Type 2 diabetes. Clinical Lipidology 6:5, pages 539-547.
Read now
Read now
André J Scheen. (2011) Cytochrome P450-mediated cardiovascular drug interactions. Expert Opinion on Drug Metabolism & Toxicology 7:9, pages 1065-1082.
Read now
Read now
Articles from other publishers (51)
Tejaswini Arunachala Murthy, Marianne Chapman, Karen L Jones, Michael Horowitz & Chinmay S Marathe. (2023) Inter-relationships between gastric emptying and glycaemia: Implications for clinical practice. World Journal of Diabetes 14:5, pages 447-459.
Crossref
Crossref
Burak Menekşe & Adnan Batman. (2023) Effect of Exenatide on Nonalcoholic Steatohepatitis and Inflammation-Related Indices in Diabetic Patients with Non-Alcoholic Fatty Liver Disease. Metabolic Syndrome and Related Disorders 21:4, pages 205-213.
Crossref
Crossref
Belma Turan, Aysegul Durak, Yusuf Olgar & Erkan Tuncay. (2022) Comparisons of pleiotropic effects of SGLT2 inhibition and GLP-1 agonism on cardiac glucose intolerance in heart dysfunction. Molecular and Cellular Biochemistry 477:11, pages 2609-2625.
Crossref
Crossref
Jelena Vekic, Aleksandra Zeljkovic, Aleksandra Stefanovic, Rosaria Vincenza Giglio, Marcello Ciaccio & Manfredi Rizzo. (2021) Diabetes and Colorectal Cancer Risk: A New Look at Molecular Mechanisms and Potential Role of Novel Antidiabetic Agents. International Journal of Molecular Sciences 22:22, pages 12409.
Crossref
Crossref
Melanie Reijrink, Stefanie A. De Boer, Anniek M. Van Roon, Riemer H. J. A. Slart, Bernadette O. Fernandez, Martin Feelisch, Hiddo J. L. Heerspink, Harry Van Goor, Jan-Luuk Hillebrands & Douwe J. Mulder. (2021) Plasma Nitrate Levels Are Related to Metabolic Syndrome and Are Not Altered by Treatment with DPP-4 Inhibitor Linagliptin: A Randomised, Placebo-Controlled Trial in Patients with Early Type 2 Diabetes Mellitus. Antioxidants 10:10, pages 1548.
Crossref
Crossref
Xin-Miao Chang, Fei Xiao, Qi Pan, Xiao-Xia Wang & Li-Xin Guo. (2021) Sitagliptin attenuates endothelial dysfunction independent of its blood glucose controlling effect. The Korean Journal of Physiology & Pharmacology 25:5, pages 425-437.
Crossref
Crossref
Marina Rankovic, Nevena Jeremic, Ivan Srejovic, Katarina Radonjic, Aleksandra Stojanovic, Milos Glisic, Stefani Bolevich, Sergey Bolevich & Vladimir Jakovljevic. (2020) Dipeptidyl peptidase-4 inhibitors as new tools for cardioprotection. Heart Failure Reviews 26:2, pages 437-450.
Crossref
Crossref
Ayman E El-Sahar, Nesma A Shiha, Nesrine S El Sayed & Lamiaa A Ahmed. (2021) Alogliptin Attenuates Lipopolysaccharide-Induced Neuroinflammation in Mice Through Modulation of TLR4/MYD88/NF-κB and miRNA-155/SOCS-1 Signaling Pathways. International Journal of Neuropsychopharmacology 24:2, pages 158-169.
Crossref
Crossref
Sergio Pinheiro, Erick M. C. Pinheiro, Estela M. F. Muri, Jaqueline C. Pessôa, Mayara A. Cadorini & Sandro J. Greco. (2020) Biological activities of [1,2,4]triazolo[1,5-a]pyrimidines and analogs. Medicinal Chemistry Research 29:10, pages 1751-1776.
Crossref
Crossref
Rosaria Vincenza Giglio, Dragana Nikolic, Giovanni Li Volti, Anca Pantea Stoian, Yajnavalka Banerjee, Antonio Magan-Fernandez, Giuseppa Castellino, Angelo Maria Patti, Roberta Chianetta, Carlo Castruccio Castracani, Giuseppe Montalto, Ali A. Rizvi, Giorgio Sesti & Manfredi Rizzo. (2020) Liraglutide Increases Serum Levels of MicroRNA-27b, -130a and -210 in Patients with Type 2 Diabetes Mellitus: A Novel Epigenetic Effect. Metabolites 10:10, pages 391.
Crossref
Crossref
Xindi Shan, Xueliang Wang, Hao Jiang, Chao Cai, Jiejie Hao & Guangli Yu. (2020) Fucoidan from Ascophyllum nodosum Suppresses Postprandial Hyperglycemia by Inhibiting Na+/Glucose Cotransporter 1 Activity. Marine Drugs 18:9, pages 485.
Crossref
Crossref
Anastasia-Stefania Alexopoulos, Ali Qamar, Kathryn Hutchins, Matthew J. Crowley, Bryan C. Batch & John R. Guyton. (2019) Triglycerides: Emerging Targets in Diabetes Care? Review of Moderate Hypertriglyceridemia in Diabetes. Current Diabetes Reports 19:4.
Crossref
Crossref
Angelo Maria Patti, Dragana Nikolic, Antonio Magan-Fernandez, Rosaria Vincenza Giglio, Giuseppa Castellino, Roberta Chianetta, Roberto Citarrella, Egle Corrado, Francesca Provenzano, Vincenzo Provenzano, Giuseppe Montalto, Ali A. Rizvi & Manfredi Rizzo. (2019) Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabetes: An 8-month prospective study. Diabetes Research and Clinical Practice 149, pages 163-169.
Crossref
Crossref
Ana Patrícia Marques, Janete Cunha-Santos, Helena Leal, Lígia Sousa-Ferreira, Luís Pereira de Almeida, Cláudia Cavadas & Joana Rosmaninho-Salgado. (2018) Dipeptidyl peptidase IV (DPP-IV) inhibition prevents fibrosis in adipose tissue of obese mice. Biochimica et Biophysica Acta (BBA) - General Subjects 1862:3, pages 403-413.
Crossref
Crossref
Bongkun ChoiSahmin LeeSang-Min KimEun-Jin LeeSun Ro LeeDae-Hee KimJeong Yoon JangSang-Wook KangKi-Up LeeEun-Ju ChangJae-Kwan Song. (2017) Dipeptidyl Peptidase-4 Induces Aortic Valve Calcification by Inhibiting Insulin-Like Growth Factor-1 Signaling in Valvular Interstitial Cells. Circulation 135:20, pages 1935-1950.
Crossref
Crossref
Patricia Freitas Corradi, Nidhi Agrawal, Namrata Gumaste & Ira J. Goldberg. 2017. Principles of Diabetes Mellitus. Principles of Diabetes Mellitus
533
550
.
Manfredi Rizzo, Ali A. Rizvi, Angelo Maria Patti, Dragana Nikolic, Rosaria Vincenza Giglio, Giuseppa Castellino, Giovanni Li Volti, Massimiliano Caprio, Giuseppe Montalto, Vincenzo Provenzano, Stefano Genovese & Antonio Ceriello. (2016) Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study. Cardiovascular Diabetology 15:1.
Crossref
Crossref
Gloria Torres, Pablo E. Morales, Marina Garc?a-Miguel, Ignacio Norambuena-Soto, Benjam?n Cartes-Saavedra, Gonzalo Vidal-Pe?a, David Moncada-Ruff, Fernanda Sanhueza-Olivares, Alejandra San Mart?n & Mario Chiong. (2016) Glucagon-like peptide-1 inhibits vascular smooth muscle cell dedifferentiation through mitochondrial dynamics regulation. Biochemical Pharmacology 104, pages 52-61.
Crossref
Crossref
Peter M. Nilsson & Javier Diez. (2016) DPP-4 inhibition and blood pressure lowering in perspective. Journal of Hypertension 34:2, pages 184-187.
Crossref
Crossref
Angelo Maria Patti, Niki Katsiki, Dragana Nikolic, Khalid Al-Rasadi & Manfredi Rizzo. (2014) Nutraceuticals in Lipid-Lowering Treatment. Angiology 66:5, pages 416-421.
Crossref
Crossref
Hyo Eun ParkJooyeong JeonIn-Chang HwangJidong SungSeung-Pyo LeeHyung-Kwan KimGoo-Yeong ChoDae-Won SohnYong-Jin Kim. (2015) Effect of Dipeptidyl Peptidase-4 Inhibitor on All-Cause Mortality and Coronary Revascularization in Diabetic Patients. Journal of Cardiovascular Ultrasound 23:4, pages 233.
Crossref
Crossref
Patricia Freitas Corradi, Nidhi Agrawal, Namrata Gumaste & Ira J. Goldberg. 2016. Principles of Diabetes Mellitus. Principles of Diabetes Mellitus
1
19
.
Manfredi Rizzo, Manisha Chandalia, Angelo Maria Patti, Vittoria Di Bartolo, Ali A Rizvi, Giuseppe Montalto & Nicola Abate. (2014) Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. Cardiovascular Diabetology 13:1.
Crossref
Crossref
Liya Wu & Klaus G. Parhofer. (2014) Diabetic dyslipidemia. Metabolism 63:12, pages 1469-1479.
Crossref
Crossref
Manfredi Rizzo, Rosaria Vincenza Giglio, Dragana Nikolic, Angelo Maria Patti, Claudia Campanella, Massimo Cocchi, Niki Katsiki & Giuseppe Montalto. (2013) Effects of Chitosan on Plasma Lipids and Lipoproteins. Angiology 65:6, pages 538-542.
Crossref
Crossref
Manfredi Rizzo, Dimitri P. Mikhailidis & Khalid Al-Rasadi. (2014) The Effects of Anti-Diabetic Drugs on LDL Subclasses: Any Role for Colesevelam?. Cardiovascular Drugs and Therapy 28:3, pages 205-207.
Crossref
Crossref
Swneke D. Bailey, Changchun Xie, Guillaume Paré, Alexandre Montpetit, Viswanathan Mohan, Salim Yusuf, Hertzel Gerstein, James C. Engert & Sonia S. Anand. (2013) Variation at the DPP4 locus influences apolipoprotein B levels in South Asians and exhibits heterogeneity in Europeans related to BMI. Diabetologia 57:4, pages 738-745.
Crossref
Crossref
Yifei Zhang, Jie Hong, Jie Chi, Weiqiong Gu, Guang Ning & Weiqing Wang. (2014) Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials. Diabetes/Metabolism Research and Reviews 30:3, pages 241-256.
Crossref
Crossref
Christine Bernsmeier, Anne C. Meyer-Gerspach, Lea S. Blaser, Lia Jeker, Robert E. Steinert, Markus H. Heim & Christoph Beglinger. (2014) Glucose-Induced Glucagon-Like Peptide 1 Secretion Is Deficient in Patients with Non-Alcoholic Fatty Liver Disease. PLoS ONE 9:1, pages e87488.
Crossref
Crossref
Ellen de Graaf-Roelfsema. (2014) Glucose homeostasis and the enteroinsular axis in the horse: A possible role in equine metabolic syndrome. The Veterinary Journal 199:1, pages 11-18.
Crossref
Crossref
Erika Paniago Guedes, Alexandre Hohl, Thais Gomes de Melo & Felipe Lauand. (2013) Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment. Diabetology & Metabolic Syndrome 5:1.
Crossref
Crossref
Gagik Radikovich Galstyan. (2013) EDGE study in Russian Federation: efficacy and safety of vildagliptine in comparison with other oral antidiabetic agents in patients with type 2 diabetes mellitus. Diabetes mellitus 16:2, pages 82-87.
Crossref
Crossref
Dong Yang, Yukako Nakajo, Koji Iihara, Hiroharu Kataoka & Hiroji Yanamoto. (2013) Alogliptin, a dipeptidylpeptidase-4 inhibitor, for patients with diabetes mellitus type 2, induces tolerance to focal cerebral ischemia in non-diabetic, normal mice. Brain Research 1517, pages 104-113.
Crossref
Crossref
M. Burgmaier, C. Heinrich & N. Marx. (2013) Cardiovascular effects of GLP‐1 and GLP‐1‐based therapies: implications for the cardiovascular continuum in diabetes?. Diabetic Medicine 30:3, pages 289-299.
Crossref
Crossref
André J. Scheen. (2013) Cardiovascular effects of gliptins. Nature Reviews Cardiology 10:2, pages 73-84.
Crossref
Crossref
L. Pala & C. M. Rotella. (2013) The Role of DPP4 Activity in Cardiovascular Districts: In Vivo and In Vitro Evidence. Journal of Diabetes Research 2013, pages 1-5.
Crossref
Crossref
Pegah Yousefzadeh & Xiangbing Wang. (2013) The Effects of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Disease Risks in Type 2 Diabetes Mellitus. Journal of Diabetes Research 2013, pages 1-6.
Crossref
Crossref
W. Rathmann, K. Kostev, J. B. Gruenberger, M. Dworak, G. Bader & G. Giani. (2013) Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis. Diabetes, Obesity and Metabolism 15:1, pages 55-61.
Crossref
Crossref
Jeffrey S. Freeman & Edward S. Horton. (2012) What Have We Learned About the Treatment of Type 2 Diabetes? The Evolving Paradigms. American Journal of Therapeutics 19:6, pages 449-464.
Crossref
Crossref
F. Vittone, A. Liberman, D. Vasic, R. Ostertag, M. Esser, D. Walcher, A. Ludwig, N. Marx & M. Burgmaier. (2012) Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe −/− mice. Diabetologia 55:8, pages 2267-2275.
Crossref
Crossref
Steven G. Chrysant & George S. Chrysant. (2012) Clinical Implications of Cardiovascular Preventing Pleiotropic Effects of Dipeptidyl Peptidase-4 Inhibitors. The American Journal of Cardiology 109:11, pages 1681-1685.
Crossref
Crossref
André J. Scheen. (2012) Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: Yes. European Journal of Internal Medicine 23:2, pages 126-131.
Crossref
Crossref
P.-J. Guillausseau, D. Lévy, M. Virally-Kévorkian, M. Laloi-Michelin, J. Bitu, D. Sène & J.-P. Kévorkian. (2012) Diabète de type 2, antidiabétiques oraux et complications cardiovasculaires. Médecine des Maladies Métaboliques 6:1, pages 38-42.
Crossref
Crossref
Till Freudenberger & Jens W. Fischer. 2012. Inflammation and Atherosclerosis. Inflammation and Atherosclerosis
555
581
.
B. Ahrén. (2011) The future of incretin-based therapy: novel avenues-novel targets. Diabetes, Obesity and Metabolism 13, pages 158-166.
Crossref
Crossref
Daniela Lamers, Susanne Famulla, Nina Wronkowitz, Sonja Hartwig, Stefan Lehr, D. Margriet Ouwens, Kristin Eckardt, Jean M. Kaufman, Mikael Ryden, Stefan Müller, Franz-Georg Hanisch, Johannes Ruige, Peter Arner, Henrike Sell & Juergen Eckel. (2011) Dipeptidyl Peptidase 4 Is a Novel Adipokine Potentially Linking Obesity to the Metabolic Syndrome. Diabetes 60:7, pages 1917-1925.
Crossref
Crossref
Selma B. Souto, Eliana B. Souto, Daniel C. Braga & José L. Medina. (2011) Prevention and current onset delay approaches of type 2 diabetes mellitus (T2DM). European Journal of Clinical Pharmacology 67:7, pages 653-661.
Crossref
Crossref
Bo Ahrén. (2011) Are Sulfonylureas Less Desirable Than DPP-4 Inhibitors as Add-on to Metformin in the Treatment of Type 2 Diabetes?. Current Diabetes Reports 11:2, pages 83-90.
Crossref
Crossref
Jun Murai, Masafumi Koga, Hiroshi Saito, Mikio Mukai, Soeko Matsumoto & Soji Kasayama. (2011) Profiles of atherosclerotic risk factors in gastrectomized men. Endocrine Journal 58:8, pages 657-662.
Crossref
Crossref
Jian Wu, Javier Ruiz-Rodríguez, Jeanne M. Comstock, Jesse Z. Dong & Jeffrey W. Bode. (2011) Synthesis of human GLP-1 (7–36) by chemoselective α-ketoacid–hydroxylamine peptide ligation of unprotected fragments. Chemical Science 2:10, pages 1976.
Crossref
Crossref
Robert P. Brigance, Wei Meng, Aberra Fura, Thomas Harrity, Aiying Wang, Robert Zahler, Mark S. Kirby & Lawrence G. Hamann. (2010) Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes. Bioorganic & Medicinal Chemistry Letters 20:15, pages 4395-4398.
Crossref
Crossref